Fecal Microbiota Transplantation (FMT) as a Prophylaxis of Necrotizing Enterocolitis (NEC)—Protocol for a Safety Study
Open Access
- 9 March 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (3) , 437
Abstract
Background/Objectives: Necrotizing enterocolitis (NEC) is an inflammatory disease with an incidence of about one in 1000 live births, much higher in premature and low birth weight newborns. Intestinal dysbiosis is an important element in the pathogenesis of NEC, and for this reason, experimental models have been used to administer fecal microbiota transplants (FMTs) for prophylaxis and treatment of NEC with very satisfactory results. The primary endpoint of the study is safety, defined as the incidence of adverse events (AEs) and serious adverse events (SAEs) occurring from the time of intervention until hospital discharge, classified according to severity and assessed for relatedness to the intervention. Methods: This prospective, single-arm, open-label clinical study will include 20 infants born between 24 0/7 and 36 6/7 weeks of gestation. FMTs will be administered twice as a deep rectal infusion via a Foley catheter. The donors of the material from which the FMT will be prepared will be women in the third trimester of pregnancy. The safety of the therapy will be assessed by comparison with a control group, i.e., 20 patients who will meet the same inclusion criteria and will not meet any of the exclusion criteria, subject to the same hospital observation but without undergoing any medical/therapeutic intervention other than the collection of biological material. Discussion: The study will provide data on the safety and initial efficacy of FMT in this group of patients, which will allow for further research into the use of this method in the prevention of infections and NEC. Ethics: The study protocol was approved by the Bioethics Committee of the Medical University of Warsaw, Warsaw, Poland (KB/52/2025). All procedures will follow the principles of the Declaration of Helsinki. The results of the study will be submitted for knowledge translation in peer-reviewed journals and presented at national and international pediatric society conferences. Clinical Trial Registration: The study is registered at ClinicalTrials.gov: ID: NCT06333405.Keywords
Funding Information
- Pediatric Surgery Clinic of the Medical University of Warsaw
This publication has 30 references indexed in Scilit:
- Necrotizing enterocolitis: recent advances in treatment with translational potentialPediatric Surgery International, 2023
- Fecal microbiota transplantation in patients with acute and chronic graft‐versus‐host disease—spectrum of responses and safety profile. Results from a prospective, multicenter studyAmerican Journal of Hematology, 2020
- Fecal microbiota transplantation by enema reduces intestinal injury in experimental necrotizing enterocolitisJournal of Pediatric Surgery, 2020
- The protective effects of fecal microbiota transplantation in an experimental model of necrotizing enterocolitisJournal of Pediatric Surgery, 2019
- Formula versus donor breast milk for feeding preterm or low birth weight infantsCochrane Database of Systematic Reviews, 2019
- Fecal microbiota transplantation (FMT) could reverse the severity of experimental necrotizing enterocolitis (NEC) via oxidative stress modulationFree Radical Biology and Medicine, 2017
- Etiology and medical management of NECEarly Human Development, 2016
- Serious Congenital Heart Disease and Necrotizing Enterocolitis in Very Low Birth Weight NeonatesJournal of the American College of Surgeons, 2015
- Mortality of necrotizing enterocolitis expressed by birth weight categoriesJournal of Pediatric Surgery, 2009
- Considerations in determining sample size for pilot studiesResearch in Nursing & Health, 2008